Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Beck

Sleep Medicine Batavia, OH Medical Doctor

NPI 1841302551 CMS profile 956757

2055 Hospital Dr, Ste 200, Batavia, OH 45103

Open in the dashboard

General payments

$2,910

93 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Beck of Batavia, OH is reported in the CMS Open Payments database as having received $2,910 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $766 35
2024 General $1,001 16
2023 General $571 15
2022 General $349 20
2021 General $149 3
2020 General $15 1
2019 General $59 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Beck
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to David Beck were reported at $766. Among 670 Sleep Medicine profiles paid that year, the median was $439 and the middle half received between $127 and $1,274.

Show as a table
Year David Beck Sleep Medicine median Middle half National median
2019 $59 $185 $66–$736 $163
2020 $15 $149 $46–$504 $114
2021 $149 $191 $62–$750 $132
2022 $349 $246 $92–$972 $149
2023 $571 $321 $119–$1,033 $160
2024 $1,001 $393 $111–$1,207 $164
2025 $766 $439 $127–$1,274 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $1,348 28 payments
  2. GlaxoSmithKline, LLC. $450 40 payments
  3. Actelion Pharmaceuticals US, Inc. $325 3 payments
  4. Ethicon Inc. $263 8 payments
  5. Medical Device Business Services, Inc. $249 6 payments
  6. Lilly USA, LLC $117 1 payment
  7. Pulmonx Corporation $63 2 payments
  8. Vapotherm Inc $36 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $17 1 payment
  10. Genzyme Corporation $16 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,160 86 payments
  2. Travel and Lodging $634 5 payments
  3. Education $80 1 payment
  4. Gift $36 1 payment
Products named General payments · program years 2019–2025
  1. INSPIRE $1,348 28 payments
  2. OPSUMIT $325 3 payments
  3. UPTRAVI $325 3 payments
  4. Monarch Platform $263 8 payments
  5. NUCALA $249 20 payments
  6. TRELEGY ELLIPTA $163 17 payments
  7. ZEPBOUND $117 1 payment
  8. CHARTIS CATHETER $63 2 payments
  9. ZEPHYR DELIVERY CATHETER $63 2 payments
  10. ZEPHYR ENDOBRONCHIAL VALVE $63 2 payments
  11. Other $238 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,069

Median for Pulmonary Disease: 936

Drug cost

$460,476

Median for Pulmonary Disease: $487,987

Branded share of claims

66.2%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 237 $223,240
Dupixent Pen Dupilumab Brand 23 $85,889
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 65 $46,614
Spiriva Handihaler Tiotropium Bromide Brand 37 $25,625
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 20 $12,662
Breo Ellipta Fluticasone/Vilanterol Brand 27 $12,359
Spiriva Respimat Tiotropium Bromide Brand 19 $10,572
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 18 $8,511
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 12 $7,760
Arnuity Ellipta Fluticasone Furoate Brand 13 $6,157

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$47,109

Medicare's payments for the services billed

Medicare patients

322

Average age 73

Services billed

641

159 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 56%
COPD 53%
Diabetes 42%
Heart failure 36%
Depression 34%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record